Business US
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why. – The Washington Post
- Some people are getting shut out when it comes to GLP-1 drugs. Here’s why. The Washington Post
- CEO of major Mass. health insurer discusses choice to restrict GLP-1 weight-loss drugs The Boston Globe
- The GLP-1 paradox: too expensive to cover, too effective to cut Fortune
- The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients ScienceDaily
- Controversy surrounding diabetes drug, Ozempic, being used for weight loss LiveNOW from FOX
